MedTrace Logo

Interferon Alfa in Treating Patients With Advanced Kidney Cancer

NCT00003542 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2013-06-25

No results posted yet for this study

Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells.

PURPOSE: Phase I/II trial to study the effectiveness of interferon alfa in treating patients with advanced kidney cancer.

Conditions

Interventions

BIOLOGICAL

pegylated interferon alfa

Sponsors & Collaborators

Principal Investigators

  • Robert J. Motzer, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Primary Completion
2004-04-30
Completion
2004-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003542 on ClinicalTrials.gov